Peptide Substrate for Complement Activation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and monitoring of complement activation in the eye, particularly for identifying high-risk drusen associated with age-related macular degeneration (AMD), which hinders early diagnosis and progression prediction.
Innovation Solution
A method involving the administration of a substrate for complement activation pathway proteases, such as a peptide substrate for C3 convertase, to detect cleavage and generate a detectable signal, allowing for the assessment of complement activation and inflamed endothelium in the eye, enabling the identification of high-risk drusen and predicting AMD progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used, then AMD can be diagnosed, but early detection of high-risk drusen and complement activation is not achieved
Solution Approach 1:
The invention administers a substrate for complement activation pathway proteases to the subject before actual complement activation occurs. This preliminary action allows the substrate to be present and ready to detect complement activation at its earliest stages, enabling early detection of high-risk drusen and timely intervention before significant vision loss occurs.
Solution Approach 2:
The invention uses a substrate as an intermediary molecule that mediates between the complement activation pathway proteases and the detection system. The substrate is specifically designed to be cleaved by complement activation pathway proteases, producing a detectable signal that indicates complement activation, thereby enabling indirect but sensitive detection of the biological process.
2Reliability
If current methods are used, then AMD diagnosis is possible, but effective monitoring of complement activation is not achieved
Solution Approach 1:
The substrate acts as a specific intermediary that selectively interacts with complement activation pathway proteases. This specificity ensures reliable detection of complement activation without cross-reactivity with other proteases, while the detection system remains relatively simple by measuring only the cleavage product or signal change from the substrate.
Solution Approach 2:
The substrate is designed to produce a detectable signal upon cleavage, which may involve color changes, fluorescence changes, or other optical signals. This allows reliable visual or instrumental detection of complement activation status, providing clear binary or quantitative readout of the biological process without complex analytical equipment.
3Difficulty of detecting and measuring
If substrate administration is performed, then complement activation detection is enabled, but additional administration step is required
Solution Approach 1:
The substrate serves as a convenient intermediary that simplifies the detection process by converting an otherwise difficult-to-measure biological process (complement activation) into a simple detectable signal (substrate cleavage). Although administration is required, the subsequent detection is greatly simplified, and the substrate can be administered systemically with good bioavailability.
Solution Approach 2:
The invention replaces complex mechanical or invasive detection methods with a biochemical assay based on substrate cleavage. Instead of directly imaging or measuring complement activation through complex equipment, the system uses a biochemical reaction (protease cleavage of substrate) that produces a simple detectable signal, substituting mechanical complexity with biochemical simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of high-risk drusen and complement activation, facilitating timely intervention and improving the prediction of AMD progression, thereby aiding in the management and treatment of AMD.
Implementation Method 1
detecting cleavage of the substrate, thereby detecting complement activation in the subject
Implementation Method 2
the substrate produces a detectable signal upon cleavage... the substrate is a fluorogenic substrate... cleavage of the substrate produces a fluorescent, visible, magnetic, or infrared signal
Implementation Method 3
the substrate comprises a peptide substrate for a C3 convertase linked to a first moiety and a second moiety, wherein the first and second moiety are a FRET pair
Data Source
AI summary
In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments any of the methods further comprises treating a subject at risk of developing AMD, GA, or advanced AMD or at increased likelihood of rapid progression of AMD with a complement inhibitor. In some aspects, agents useful for performing one or more of the methods are described.